XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.67

-10.7%

Jan 12 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Cacaito who wrote (10398)	6/10/1999 4:19:00 PM
From: Edward Paule	of 17367

>>>>>>>> I would have like more a Phase III trial on abdominal infections (great phase II results)for a clearcut gram-negative indication. I do think they will go ahead with a phase III in due time. <<<<<<<<<< >>>>>>>> for a clearcut gram-negative indication <<<<<<<< >>>>>>>> for a clearcut gram-negative indication <<<<<<<< I've bemoaned this for years. This is my NUMBER ONE problem with Xoma's trial designs. All the research indicates rBPI21 will only work on gram-negative bugs. So why waste time and money persuing non-gram-negative indications? Less than half of ARDS patients have a gram-negative infection. Less than half of Cystic Fibrosis patients have a gram-negative infection. Partial heptecomy ???. Is it so hard to find other indications like meningo and pnuemonia that are mostly/all gram-negative? I can only assume it's an FDA labelling issue. If successful in a broad indication, the drug can be given to everybody (more sales). If the drug was only tested in known gram-negative cases, would the labelling indicate that a gram-negative infection be tested for and confirmed in the patient prior to administering the drug? Just my opinions, Ed.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next